Sarah qualified from the Royal Veterinary College in 1998, gained an MSc in Clinical Oncology in 2003, the RCVS Certificate in Veterinary Dermatology in 2010 and RCVS Advanced Practitioner status in 2015. She is now the President of the British Veterinary Dermatology Study Group.
Sarah previously ran two dermatology referral services before co-founding Vet-AI, a company working on artificial intelligence and an online consultation service for pet owners, where she is now the Chief Veterinary Officer.
Sarah said: "Many diseases that are primarily non-pruritic often become pruritic when the animal develops secondary bacterial or yeast infection. These cases require a thorough dermatologic history and physical examination and successful treatment very often depends on identification of the underlying cause."
"Providing the right nutrition should also be implemented to ensure optimal levels of nutrients required for skin repair, barrier function and health. I will be including a complete pruritus work up, discussing how diet can be part of the management of this particular condition."
To register for the webinar, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
Vetoquinol has announced the launch of Enisyl-FTM, the first L-Lysine supplement developed for veterinary use in the UK and Ireland.
Vetoquinol says a unique distributing pump and paste formulation will aid compliance in cats that require L-Lysine supplementation and make administration of L-Lysine much easier. Each pump action delivers 1ml of Enisyl-F paste at each press, which can be applied directly into the cat's mouth or on the paw to be licked off. It can also be added to food.
Zorica Agbaba, Enisyl-F's Product manager said: "We are delighted to have launched Enisyl-F and I am sure it will prove very useful to veterinary surgeons, especially when it comes to aiding compliance in cats that require L-Lysine supplementation."
To try Enisyl-F or for more information about the product, contact your local Vetoquinol representative or call Vetoquinol main office on 01280 814 500 (UK) or 1800 406 117 (ROI free phone number). Alternatively visit http://www.vetoquinol.co.uk/ website.
Petplan has announced that Richard Williams MRCVS from the Vale Veterinary Centre in Barry has won its Vet of the Year award.
The award is one of a number handed out each year to celebrate exceptional veterinary surgeons, nurses, practices, practice managers and vet support staff who have gone above and beyond the call of duty in keeping pets healthy and giving owners peace of mind.
The independent panel of judges was particularly impressed with Richard’s tireless dedication to veterinary care. They said: "He is considered by both clients and colleagues to be a great communicator, is constantly researching new and improved techniques, is brilliant at motivating staff and proactively encourages the professional development of his team – he truly leads by example."
On receiving the award, Richard said: "I’m completely surprised, overjoyed and humbled that my clients have taken the time out of their busy days to vote. It’s a great feeling."
Other winners included:
Isabella von Mesterhazy, Head of Marketing at Petplan, said: "Through the annual Petplan Veterinary Awards we’re able to pay tribute to the incredible work carried out by members of the veterinary profession across the UK. Their dedication allows pet owners to rest safe in the knowledge that, whether it’s for a routine check-up, an unexpected illness or injury or a simple procedure, their much-loved pets are in safe hands when they visit their vets. We’re elated to be able to announce the deserving winners, and congratulate them on such a fantastic achievement!"
For more information about the awards and to learn more about the winners, please visit http://www.petplan.co.uk/vetawards/winners.asp.
The two-month campaign is comprised of a series of very polished videos which are now being shared on YouTube.
The videos share the experiences of a number of veterinary professionals from PSS practices who talk to the camera first as owners themselves, and then as vets.
The College says the aim is to demonstrate to the public that their animals will receive veterinary care from empathetic practice teams committed to delivering the kind of veterinary care they would want for their own animals.
Mandisa Greene, Chair of the Practice Standards Group, said: "In order for a veterinary practice to be accredited under the Practice Standards Scheme it needs to demonstrate that it is meeting a broad range of stringent standards and undergo a rigorous independent assessment every four years.
"However, we know that awareness and understanding of the Scheme amongst animal owners is relatively low, and that there is always more we can do to help change this. We have therefore developed this digital campaign to help RCVS-accredited practices explain to animal owners what RCVS-accreditation means, and why they should care about it.
"We think it’s important that RCVS-accredited practices, which go through a great deal of effort and work to achieve their accreditation, receive the recognition they deserve and we hope that they will help us to spread the word far and wide."
Ian Holloway, RCVS Director of Communications, said: “A vital ingredient of this campaign will be the support and involvement of RCVS-accredited practice teams right across the country. Throughout the two-month campaign, we will be posting lots of wonderful video stories, pictures and PSS infographics across all of our social media channels, along with other fun ways to help spread the word.
"We’re posting launch packs to all accredited-practice premises this week, which include a variety of campaign posters to display in waiting rooms and details of how to download all the digital resources from our campaign website for use in practice and online.
"We really hope that everyone associated with an RCVS-accredited practice, including their clients, will be able to share this campaign across their own channels as widely as possible, remembering to use the campaign hashtag #YourKindOfVets, of course!"
Anyone wanting more information about the campaign should email: yourkindofvets@rcvs.org.uk.
Ceva says Adaptil Junior has been proven to reduce night crying and whining by 86%2 and helps puppies to adapt to their new homes and unfamiliar situations in three days3, 4.
According to the company, puppies with Adaptil Junior are also less fearful and anxious during puppy classes, resulting in better long-term socialisation3.
Research carried out by the company found that over 60% of dog owners buy their dogs as puppies, with half of those questioned getting their dogs before they are three months old1.
Abigail King, product manager for Adaptil at Ceva Animal Health said: "Adopting a puppy is an exciting, yet challenging time with puppies facing stressful situations such as separation from their mother, socialisation, staying home alone and experiencing new sights, sounds and noises.
"Adaptil Junior is an effective, natural solution to help comfort newly adopted puppies and facilitate their education while helping them to learn and adapt to their new lives. This, in turn, will ensure that puppies get off to the best start in life, which will help keep rehoming numbers down."
Adaptil Junior comes in the form of a translucent blue collar which fits necks up to 37.5cm in circumference. The collar releases dog appeasing pheromone over a period of four weeks and should be worn continuously.
To support the launch of Adaptil Junior, Ceva Animal Health has introduced a puppy party marketing pack to provide puppy party organisers with the tools they need in order to stage puppy parties.
Produced in collaboration with the leading dog behaviourist, Gwen Bailey, the pack features display materials, webinars, gifts and literature including leaflets, puppy party invites and posters and is available with Adaptil Junior orders.
For more information, visit www.adaptil.com/uk.
References
It is hoped the survey will capture the experiences vets have had reporting ADRs, as well as identifying barriers to the current process which could be used to improve the ease with which ADRs are reported in the future.
PhD student Heather Davies (pictured right), who is leading the research project, said: "The survey is an important opportunity to gain insights into the issues that vets face when dealing with ADRs.
"We want to make the process easier in order to improve the safety of veterinary medicines, and ultimately, we need the help of professionals on the front line in order to do that."
She added: "The survey is relatively short and can be completed anonymously.
"We’re really keen to gather as many of your experiences as possible so we’d like to encourage veterinary professionals to complete it."
The research is being carried out as part of a PhD project funded by the Veterinary Medicines Directorate (VMD) in collaboration with the Small Animal Veterinary Surveillance Network (SAVSNET), based at the university.
The survey is now open and you can take part here: https://liverpool.onlinesurveys.ac.uk/adrs-vet
Any questions about the survey can be addressed directly to the researchers: Heather Davies (PhD student): H.H.Davies@liverpool.ac.uk and/or Dr David Killick (Supervisor): David.Killick@liverpool.ac.uk.
Norbrook has announced the launch of Marbodex Aural, the most recent addition to its Otitis Management System for dogs.
Norbrook says the ingredients in Marbodex Aural (marbofloxacin, clotrimazole, dexamethasone) are proven to relieve pain and inflammation quickly, deal with key bacterial and fungal infections effectively and thereby improve pet comfort.
The company says the inclusion of marbofloxacin makes Marbodex Aural an ideal first choice for cases of otitis externa that are:
Marbodex Aural also contains clotrimazole, a broad spectrum antifungal effective against otitis caused by Malassezia pachydermatis, and dexamethasone, a fast acting steroid whose absorption is not increased in inflamed ears.
Marbodex Aural is applied once a day and has two soft nozzles to reduce pain on application and prevent cross-contamination during treatment. It can be used for extended treatment periods of seven to fourteen days when treating persistent infections.
Marbodex Aural is available in all veterinary wholesalers now. For more information about Marbodex and to take advantage of the launch offers, contact your Norbrook Territory Manager or call 01536 741147 for more information.
Reference:
The paper details the current and potential uses of this rapidly developing technology, and its benefits and risks.
It provides an introduction to AI and its uses in human medicine, small animal, farm and equine practice, radiology and veterinary education.
It also looks at the potential impact on the wellbeing and working life of veterinary teams.
Results from VetCT’s recent survey on the opinions of AI within the veterinary profession are included in the paper.
Julien Labruyère, Chief Innovation Officer at VetCT, said: “This is a crucial moment in the veterinary industry to ensure we have the knowledge and safeguards in place to apply AI safely, effectively and with confidence to support good clinical practice and ultimately, improve animal welfare.
"This white paper aims to provide a firm foundation for understanding AI and stimulate discussion on how it may impact both people and animals.”
The paper also calls for the development of industry-wide guidance, standards and regulations to safeguard veterinary teams and animal health and welfare as these tools are deployed.
Julien added: “AI development is accelerating rapidly, with global governments and industries racing to regulate to ensure the benefits outweigh the potential negative impacts of this far-reaching technology.
"It’s vital that opinion leaders, organisations and regulators from across the veterinary world come together and develop guardrails so we can have confidence that AI tools will benefit our teams and our patients.”
https://5345458.hs-sites.com/vetct-ai-white-paper
Stewart Halperin (pictured right), the vet who founded CarefreeCredit, said: "We originally started out by helping vets provide loans to treat pets needing medical attention which wasn’t covered by insurance, allowing them to provide the care needed, while also being paid immediately, improving cash flow and reducing bad debts.
"With this new service, vets can make their services better known in their local communities, which will also boost their turnover and allow them to care for even more animals."
Practices that use CarefreeCredit are given access to an online application process that takes around five minutes, providing loans from £250 upwards for use against any veterinary bills.
A range of credit terms are available from 0% APR upwards. They are also the only company to offer loan rates based on risk, which they say means more clients are likely to be accepted for finance.
CarefreeCredit practices that want to use the PR service need to contact the company, whereupon they'll arrange for an award-winning public relations consultant to provide the support they need - free of charge.
For further information, visit: www.carefreecredit.co.uk or call 0345 313 0177.
Dr Neil Bryant from the AHT, who is leading the research, said: "EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world. It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease."
As a viral infection, EHV can cause respiratory disease, abortion or fatal illness in new born foals and neurological disease in adult horses, with signs ranging from slight wobbliness through to complete paralysis. The disease can strike any horse at any time because the virus, like other herpesviruses (such as the cold sore virus in humans), becomes dormant within most horses early in their life. It then re-emerges when the animal is later stressed such as when transported or mixed with new horses. A seemingly healthy pregnant mare may suddenly, and without warning, abort her unborn foal or may show signs of respiratory disease including mild fever, coughing and discharge from the nose. A horse which appears fit and well may suddenly show abnormalities when walking and within hours may be unable to stand.
Despite the potential severity and impact of outbreaks, there is still no vaccine that is licensed to protect against the neurological form of the disease and abortions still occur in highly vaccinated horse populations. The AHT says protection afforded by existing vaccines currently in use is sub-optimal, something that was highlighted by the 2016 abortion storm in Hertfordshire in fully vaccinated animals.
Neil added: "We have become aware of a pressing need for progress towards a new and improved EHV-1 vaccine. Just last month, the AHT was again called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in premises in Yorkshire and Suffolk."
To that end, the charity has now established the Equine Industries EHV Vaccine Steering Group. Chaired by Professor Joe Brownlie of the RVC, the steering group includes world-renowned experts on both human and equine herpes viruses from a number of research establishments, who have concluded that the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.
After securing funding from a large number of organisations, including the Alborada Trust, EBM Charitable Trust, Horserace Betting Levy Board and the Racing Foundation, Paul Mellon Estate, Thompson Family Charitable Trust, Coolmore Ireland, Newsells Park Stud, Thoroughbred Breeders’ Association and Juddmonte Farms, the AHT has begun its five-year research programme.
Neil added: "We’re at the beginning of a very exciting and potentially ground-breaking vaccine development. Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs. We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1."
The new product is being sold through e-retailers including Pet Drugs Online, Animed and Pets at Home.
Frontpro is claimed to kill fleas within 8 hours and protect dogs from fleas and ticks for one month.
It is suitable for all breeds aged eight weeks or older (weighing two kilograms or more) and can be given with or without food.
A company spokesperson said: "Boehringer Ingelheim is committed to expanding access to high-quality parasite prevention for dogs, which is why we’re proud to introduce an effective new option.
"Frontpro chewable tablets provide effective protection from fleas and ticks, while complementing the regular care and advice pet owners receive from their veterinarians."
www.uk.frontline.com
The 'Room For Rabbits' campaign follows research in which 38% of vets said they think rabbits’ environment is the most neglected welfare need1, with over a quarter of the UK’s rabbits being kept in inadequate housing conditions, and almost half of them living alone2.
The RAW survey also found that 90% of vets believe that rabbits’ welfare in the UK is improving3.
Room for Rabbits will throw a spotlight on rabbits’ environment, with a variety of initiatives during RAW including vet blogs and videos on how to adapt bunnies’ housing for all seasons, boredom buster ideas, a competition to encourage owners to create a RAW ‘gold standard’ environment, and downloadable packs containing resources for practices to create their own RAW campaigns.
Holly Castle, Senior Brand Manager at Burgess Pet Care, RAAG member and organisers of RAW, said: “We are delighted that RAW continues to have a positive impact, with our survey showing that 90% of vets believe that the welfare of the UK’s rabbits is improving - but there is always more than we can do.
“Since the previous RAW campaign, we have successfully launched RAAG, which recognises that the welfare of these wonderful creatures needs to be high on the agenda year-round.
"By bringing together the expertise of the RAW partners, RAAG is focused on encouraging everyone involved with rabbits to support the first Good Practice Code for rabbits’ welfare in England to ensure it becomes enshrined in law.
"One of the ways to achieve this is through initiatives like RAW, which is the UK’s largest welfare campaign of its kind.
“We recognise that vets’ practices were really stretched last year due to the Covid-19 pandemic, which meant it was difficult to support campaigns like RAW.
"However, following a surge in demand for rabbit ownership in the UK during the past two years, it is vitally important that we educate more owners than ever before and continue to help improve rabbits’ welfare."
“The veterinary community plays a hugely important role in ensuring that owners have access to the right information, and we are urging practices to throw their support behind this year’s RAW to ensure that we reach as many owners as possible.
Professor Ian Ramsey, Past President of the BSAVA, which endorses RAW, said: "The BSAVA is once again delighted to support RAW and the theme of this year’s campaign.
"Rabbits remain one of the most misunderstood pets in the UK, but we are confident that vets across the UK will again show their support for this important campaign to improve the lives of pet rabbits.”
The RAAG is encouraging vets’ practices to sign up to receive updates about RAW at https://www.rabbitawarenessactiongroup.co.uk/raw-pack-reminder/.
Downloadable RAW vet packs will also be available from 6th June.
Vetoquinol is launching Forcyl, an injectable anti-infective for the targeted therapeutic treatment of respiratory infections in cattle, in November.
Forcyl is a patented 16% marbofloxacin solution, registered as a single intramuscular injection, which the company says will ensure a high level of compliance.
Forcyl follows the SISAAB concept (single injection short acting antibiotic), with an optimised dosage to minimise the risk of development of antibiotic resistance. Shorter exposure time limits the opportunity for resistance to develop. The formulation means a lower volume of administration (10 ml for 160 kg body weight) is required. Vetoquinol says that other benefits of Forcyl include excellent injection site tolerance and short withdrawal periods (meat: 5 days, milk: 48 hours).
For further information on implementing the SISAAB concept in your practice, please contact one of Vetoquinol's large animal team on 01280 814500.
Merial has launched Supleneo flex, a nutraceutical supplement designed to be part of a Total Joint Health programme for dogs, administered once daily.
Merial says the new product supports its market position as a leading force in canine pain management, supported by the canine NSAID Previcox.
According to the company, Supleneo flex is suitable for all breeds, sizes and ages, and contains three key ingredients associated with joint health: glucosamine hydrochloride, chondroitin sulphate and mixed tocopherols (Vitamin E). It is designed to be used as part of an all-round joint care programme, alongside nutrition, weight management and exercise.
Merial says the soft chews are highly palatable and when tested against a range of competitor products, a significant difference was observed, with Supleneo flex readily taken and preferred by dogs.1
Supleneo flex is supported by printed and digital materials to help with owner education, including a waiting room video and an online information website at www.supleneoflex.co.uk for clients.
For veterinary surgeons, Merial is offering product advertising support and a loyalty programme.
For more information, telephone Merial on 0870 6000 123 or contact your Territory Manager.
Eurovet Animal Health has launched a new product, Bovocycline 2000 mg pessary for cattle.
Bovocycline 2000 is the only veterinary licenced antibiotic pessary for the treatment of retained foetal membranes in cattle. It is licenced for the treatment of post parturient disorders in cattle, for administration after dystocia, retained foetal membranes (RFMs) and endometritis.
According to Eurovet, the incidence of retained foetal membranes in cows varies from zero to 25 per cent, but the average is around 4 per cent in most herds. RFMs result in reduced cow fertility and a higher risk of culling due to poor fertility. Pessaries are still considered the preferred treatment for vulval discharges in cattle by farmers.
Ruth Vernon, Technical Services Manager for Eurovet said: "The control of post partum problems in cattle is rarely straight forward, but it is great to have a veterinary licensed treatment designed specifically for this purpose, in one pessary that contains 2000mgs tetracycline".
For more information please contact Eurovet Animal Health. Tel: 01223 257933. E-mail: office@eurovet-ah.co.uk www.eurovet-ah.co.uk
Bayer Animal Health has announced that it will launch Seresto, a new POM-V collar for cats and dogs that kills fleas and repels and kills ticks for up to eight months, in March.
According to Bayer, Seresto is the first treatment to provide repellency against ticks in both cats and dogs, and represents the fruit of a multidisciplinary effort incorporating the company's research into insecticides, polymers and veterinary parasiticides. The end result is a polymer-based collar that transfers the active ingredients to the lipid layer, from where they are spread by the animal's neutral oils.
Bayer Animal Health group product manager, Caroline Braidwood, said: "Seresto is simple to use on both cats and dogs. And because it is long lasting, it offers pet owners an alternative to those struggling to maintain a monthly routine. Bayer believes in innovation and Seresto is an enhancement to our product portfolio that meets the needs and requirements of pet owners and vets alike in the treatment of ticks and fleas."
Seresto contains two active ingredients - imidacloprid for fast action against fleas and flumethrin, which repels and kills ticks.
Caroline added: "Thanks to Seresto's unique polymer structure the active ingredients are safely locked away in the collar's matrix, and are released directly from the collar surface into the lipid layer of the animal at just the dose needed, ensuring optimal protection is sustained for up to 8 months."
Bayer says that because of its repellent (anti-feeding) effect, Seresto reduces the risk of vector-borne disease transmission - a first for cats. The company also says that because the active ingredients are stored on the inside of the polymer, it doesn't matter if the pet is shampooed and the lipid layer stripped off - the active ingredients are quickly replenished by the collar.
Seresto is odour-free and has a safety release mechanism to prevent strangulation. It is available in three sizes, Seresto Cat for cats less than 8kgs, Seresto Small Dog for dogs up to 8kgs and Seresto Large Dogs, for dogs over 8kg.
For further information about Seresto, contact your Bayer territory manager or call 01635 563000.
Lynn Jo Ann Davies MRCVS first appeared before the Committee in January 2018 to face a number of charges related to two drink-driving offences, breaching the terms of her undertakings to the College as part of its Health Protocol, and being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016.
Dr Davies admitted all five charges against her and admitted that this meant she was unfit to practise veterinary surgery and that she was guilty of disgraceful conduct in a professional respect. The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At its first hearing the Committee having considered both aggravating and mitigating circumstances decided to postpone the hearing for six months on the basis of Dr Davies’ entering into a new set of undertakings, including one not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement.
At the second hearing, in July 2018, the Disciplinary Committee resumed its sanction inquiry decision. Dr Davies’ Counsel submitted on her behalf that Dr Davies wished to return to practise and the Committee reviewed her witness statements, documentary proof and medical records that she provided to demonstrate she had complied with the her undertakings given at the last hearing.
Stuart Drummond, Chairing the Committee and speaking on its behalf, said: "Having had the opportunity to see and hear from the respondent when she gave evidence and when she answered the questions put to her, the view formed of her current state of health was favourable. All members of the Committee considered that the account she gave of herself in the witness box was confident and they were reassured by her evidence as to how she now sets about managing her levels of stress and how she reacted to stressful incidents.
"Such concerns as the Committee had about her return to practice concerned her ability to receive support from a third party who would act as a mentor…the Committee therefore requires the Respondent to identify, within a period of one month of today’s date, a veterinary surgeon who would agree to act as her mentor. That mentor would have to be a veterinary surgeon acceptable to the College as someone suitable to act in that capacity and that mentor would have to be approved before the Respondent could resume practice.
"A further requirement of the Committee would be that the Respondent should make a disclosure to any new employer of the fact of her appearances before this Committee in January 2018 and in July 2018 and of the decisions of the Committee in relation to both such hearings. The final requirement of the Committee in this respect is that the respondent should not accept a 'sole charge position' at any time during her employment during this next period of postponement of sanction."
The Committee directed that the hearing be postponed for a further 12 months.
Omniotic combines three ingredients to remove ear wax and debris: a detergent, a solvent and an emulsifier. It also contains Octoxynol-9, lactic acid, salicylic acid and parabens, which Vita says have anti-fungal, anti-viral and anti-bacterial properties.
The product is sold in 120ml bottles with a transparent flexible tip designed to be comfortable even in stenosed, tender ear canals.
Omniotic can be used for regular daily cleaning, especially in predisposed breeds such as spaniels and lop-eared rabbits where ear conformation increases the risk of ear disease.
The product can also be used alongside other antibiotics or anti-fungal medications, something which Vita highlights as being especially important in rabbits, the ear canals of which are less prone to inflammation and stenosis, and for which topical treatment can be very effective.
Tara Evans, RVN and sales manager said: "Omniotic is an ear cleaner for dogs, cats and rabbits which combines features to meet the needs of owners and vets at the same time. The feedback from our customers is very positive; they are finding the soft, flexible applicator tip is easy to use and well tolerated. The unique combination of ingredients and the multi-species use means Omniotic can be used to support ear health across a wide variety of indications."
For more information and for the latest promotional offers, contact Tara Evans, via email: info@vitaanimalhealth.com, or telephone: 01256 591032.
In 2014 ioLight co-founders, Oxford physicists Andrew Monk and Richard Williams, filed a patent application for a pocket-sized digital microscope with a performance that compares with expensive laboratory microscopes. They asked Cambridge Industrial Design to realise the product, briefing them that the device would need to deliver images with one micron resolution (required to view human or animal cells) onto a smartphone or tablet, be pocket-sized, easy to use, and economical to build in medium to high volumes.
One of the biggest challenges was in making the unit pocket-sized, which meant it had to be foldable, something which could have led to a loss in the rigidity needed to achieve high resolution images. This challenge was overcome with the use of a single hinge which the company says makes the ioLight both portable and robust.
Alex Jones, Managing director of Cambridge Industrial Design said: "We recognised immediately this was a great idea but the design brief was certainly a challenge. Fortunately, challenges can sometimes bring out the best in designers. The final design is a real success both aesthetically and ergonomically, and this award is a fantastic acknowledgement for the design process and the final product that we have created together with ioLight."
ioLight is also celebrating another success: closing its second round of equity funding after raising £320k from 335 investors on the Crowdcube platform (128% of the initial target).
The company says the new funding will allow it to promote the microscope to a wide range of target markets including veterinary surgeons, education, laboratory and field research, museums and public engagement as well as to international markets.
Andrew Monk, ioLight’s co-founder said: "The product is so simple to use that it is the ideal communication tool for explaining science to the public, students and customers. The microscope lets everyone see the same image so the discussion is about the picture not the tools. It’s a perfect fit for government public engagement campaigns, which are well funded at the moment. We are absolutely delighted that this funding provides us with the opportunity for both product development and to reach out and make microscopy available to so many more people."
The practice is one of few in the UK to use radioactive iodine (RAI) therapy, which, it says, has an average, a 95% success rate in treating cats with hyperthyroidism.
Stephanie Lalor MRCVS (pictured right), an RCVS Specialist in Feline Medicine at Willows said: "The new therapy is non-invasive and is the gold standard of treatment for cats with hyperthyroidism. It is safe and highly effective and a single injection can be curative. Patients do need to be screened for their suitability and ideally they are treated with medical therapy prior to the RAI.
"Due to the radioactive nature of the treatment, patients must stay with us for 15 days after the injection. Our patients stay in luxury cat condos during their hospitalisation and their day-to-day care is over-seen by our lead radioactive iodine nurse, Vicky Maund."
The new unit is part of a £1 million investment in Willows which includes a dedicated operating theatre for minimally invasive procedures, a range of specialist treatment rooms and more than 40 new kennels.
Toby Gemmill, clinical director at Willows, said: "We are already extremely well placed to offer a wide variety of specialist treatments and this extension has provided us with the space to expand our services further. The new radioactive iodine unit is very exciting and allows us to build on our gold level cat-friendly clinic status."
For more information, visit www.willows.uk.net.
In a statement, the company explained that elevated vitamin D can cause vomiting, loss of appetite, increased thirst, increased urination, excessive drooling, and weight loss. At high levels, it can lead to serious health issues in dogs including renal dysfunction.
The company is inviting 'pet parents' (dear god, spare me) whose dogs are suffering symptoms after eating the products to contact their veterinary surgeon.
Hill's also says it will cover the cost of testing total calcium, albumin and 25OH-Vitamin D3 metabolites in animals which have consumed affected products, at the VitDAL Lab at the Edinburgh Veterinary School.
The affected products are:
Virbac points to how the pandemic has caused a fundamental shift in consumer shopping habits, with e-commerce accounting for more than 30% of retail sales in the UK in 2020 for the first time1.
Alongside the increase in online sales has come an expectation by consumers that all companies should provide a reliable digital service, with 70% saying that they will continue to buy essential goods online post-pandemic2.
At the same time, sales of pet food in the majority of veterinary practices have been hit by the need for social distancing.
Through the new model, when pet owners buy Virbac's low-carb, high protein Veterinary HPM dog and cat food from the company's new web store for home delivery, a commission is paid to the practice.
Remi Mandray, Product Manager at Virbac said: "It’s a win-win for our practices and their clients, who can take advantage of this convenient option to have their pet food delivered to their home, whilst providing the practice with a protected and rewarding business model".
For more information, contact your Virbac Territory Manager.
The BVA is also calling on Government to tighten pet import rules.
The advice follows news about a positive Brucella canis test in a rescue dog imported from Belarus in March this year.
The woman fostering the dog was hospitalised after coming into close contact with it, in the UK’s first confirmed dog-to-human transmission.
The foster animal and four pet dogs who were exposed to the disease, three of whom also tested positive, all had to be euthanised.
Data released by the Government shows a steep rise in confirmed Brucella canis cases since the start of 2020, rising from just three before that year to 107 till July this year.
The dogs were all either imported, had returned from holiday overseas, or been bred with an imported dog.
BVA is asking veterinary teams to:
British Veterinary Association President Justine Shotton said: “This recent case of Brucella canis in a foster dog is extremely tragic and highlights why vets have long raised concerns over the real and serious risks of importing ‘Trojan’ rescue dogs with unknown health histories into the UK.
“We know there is an added public health risk too, including for veterinary teams who treat and handle these animals, from contact with an infected dog’s contaminated body tissues and fluids.
"BVA continues to call on the Government to take urgent action to introduce stricter pet import measures, including mandatory pre-import testing, so we can minimise the spread of Brucella canis and other emerging diseases.
"We are also calling for the strengthening of enforcement provisions and checks on dogs brought into the country through the commercial route."
The 2021 B. canis risk view and statement by Public Health England (now UK Health Security Agency) contains vital information and recommendations for veterinary professionals: here:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/960013/20210210_Brucella_canis_statement.pdf
BVA’s recommendations on tightening pet travel legislation: https://www.bva.co.uk/uploadedFiles/Content/News,_campaigns_and_policies/Policies/Companion_animals/BVA%20Position%20on%20Pet%20Travel%20Full.pdf
To take part in the survey, which will take about ten minutes, visit: https://www.surveymonkey.co.uk/r/RepRIPorVIP.
Everyone who completes the survey will be entered into a draw to win one of three £50 Amazon vouchers.
The House of Lords debate, which is being hosted by Professor The Lord Tress of Kinross, will take place on Wednesday, 21st June 2023.
Speakers will include Donal Murphy of NOAH, Rita Dingwall of the Federation f Independent Veterinary Practices and Paul Horwood, Country Head of Farm at IVC Evidensia.
https://vma.org.uk/house-of-lords/
Bayer Animal Health has taken over the marketing and sales of the antibiotic Nisamox (tablets containing Amoxicillin and Clavulanic Acid), from Fort Dodge Animal Health.
Under the new arrangement, the design of Nisamox tablet packaging will change to reflect the change of ownership, however, Bayer says the quality of the tablets and the competitive pricing remain unchanged.
Nisamox tablets are licensed for use in cats and dogs to treat infections of the skin, urinary tract, and respiratory tract caused by susceptible Staphylococci, and also to treat enteritis and urinary tract infections caused by susceptible E.coli.
Nisamox tablets will continue to be available in three strengths: 50mg, 250mg, and 500mg. For information on Nisamox tablets, contact your Bayer territory manager.